Act2

Act2 Therapeutics is a biotechnology company focused on developing next-generation T-cell engagers (TCEs) and bispecific antibodies for the treatment of cancer and autoimmune diseases. The company's proprietary ACT2 platform is designed to overcome the limitations of current T-cell engaging therapies, such as cytokine release syndrome (CRS) and limited efficacy in solid tumors, by optimizing the binding kinetics and spatial orientation of the therapeutic molecules. Led by industry veterans with experience at Kite Pharma and Gilead, Act2 is advancing a pipeline of candidates that aim to provide safer and more potent immune-mediated cell killing. The company is currently in the pre-clinical stage, focusing on validating its lead programs in various oncology indications.